REHOVOT, Israel and BETHESDA, Md. – CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company’s patent application titled “COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS” was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National phase filing in Europe will follow.
Related: CNBX Pharmaceuticals Granted Patent in Hong Kong
Said patent application relates to several of the drug candidates on the Company’s pipeline for the treatment of various types of cancer, including CNBX RCC-33, for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study.
Related: Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
The company’s growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending. The company’s IP portfolio is focused on cancer patients and cancer treatments, and includes claims relating to Pharmaceutical Compositions, Methods and Systems.
Recent News:
- CNBX Peer-reviewed Study: “Possible Future Therapeutic Value” for CNBX Proprietary Drug Candidate
- CNBX Pharmaceuticals Announces New Patent Granted in Australia
About CNBX Pharmaceuticals:
CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com. For the latest updates on CNBX Pharmaceuticals follow the Company on [email protected], [email protected], LinkedIn https://www.linkedin.com/company/cnbx, and on Instagram @CNBX_Pharmaceuticals.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
- Minority Cannabis Academy: Social Equity in Practice
The Minority Cannabis Academy graduated its first class of 25 students in September. The Academy’s goal is to take advantage of the social equity atmosphere in New Jersey to help those most harmed by prohibition. - Marijuana Policy Project Releases Voter Guide to 2022 Governors’ Races and Cannabis Policy Reform Ahead of Midterm Election
On Tuesday, the Marijuana Policy Project (MPP) released their voter guide to 2022 governors’ races and cannabis policy reform. In 36 states, voters will be choosing their next governor on Election Day. - Green Thumb to Launch “RISE Express” Dispensaries in Florida
Green Thumb Industries Inc., a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced plans to expand its medical retail footprint in Florida through a lease agreement with Circle K, the global convenience store retailer. - Missouri AFL-CIO endorses cannabis legalization constitutional amendment
Missouri AFL-CIO president Jake Hummel on Thursday announced his organization was endorsing the proposal, which will appear on the Nov. 8 ballot as Amendment 3, calling it a “huge step forward for criminal justice reform in Missouri.” - Minnesota’s Black cannabis users far more likely to face arrest than white ones
Black Minnesotans are nearly five times as likely to be arrested on marijuana charges as white ones, according to the latest data from the Bureau of Criminal Apprehension. It’s a disparity that has persisted for years, despite data showing that Black and white residents use cannabis at similar rates. - Lawmakers ask MO governor to add cannabis legalization in special session
A bipartisan group of lawmakers and activists are calling for Missouri Gov. Mike Parson to include marijuana legalization on the agenda of the legislature’s upcoming special session. - In Brief: Pa. Governor Accepting Cannabis Pardon Requests in Sept.
Pennsylvania Gov. Tom Wolf and Lt. Gov. John Fetterman announce the PA Marijuana Pardon Program, offering expedited pardon reviews to people convicted of only minor cannabis possession for personal use. - Michigan State Police stops cannabis testing after false positives
Michigan State Police have acknowledged that its blood tests for marijuana are producing false positives for THC, and it will immediately halt testing. - Missouri Dems expect boost from cannabis, but split on specifics
Support for legalization and heartburn about the amendment’s details have led to soul-searching among Democratic Party officials across the state. The consternation is particularly acute among Black Democratic leaders. - Signatures on Nebraska medical cannabis petitions to get another look
The Nebraska Secretary of State’s Office has agreed to take another look at signatures submitted by a group seeking legalization of medical marijuana to determine if they should have been counted.